BrIDGs Operational Model

BrIDGs staff collaborate with researchers in need of preclinical therapeutics development expertise and resources to advance candidate therapeutics into clinical trials. Researchers with sufficient preliminary data can leverage BrIDGs capabilities to execute a preclinical product development plan. In general, available expertise and contract resources include synthesis, formulation, pharmacokinetic and toxicology services. Collaborators may take advantage of these resources to obtain data and clinical-grade material for use in Investigational New Drug applications to a regulatory authority such as the Food and Drug Administration.

Pre-existing intellectual property (IP) rights are retained by the owner. This allows BrIDGs to operate as a non-dilutive investment in exciting preclinical therapeutics development projects and to maximize the competitiveness of therapeutic agents for further private-sector funding.

Organizations eligible to collaborate with BrIDGs include academic and nonprofit institutions, small businesses eligible for the Small Business Innovation Research program, and NIH intramural laboratories.

To request a collaboration, interested parties must submit a formal proposal. These proposals are accepted on a rolling basis for the development of therapeutic agents for any disease or disorder. Studies may be proposed for a variety of therapeutic types, such as small molecules, peptides, oligonucleotides, gene vectors, recombinant proteins and monoclonal antibodies.